| __timestamp | BioCryst Pharmaceuticals, Inc. | MiMedx Group, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 90480000 |
| Thursday, January 1, 2015 | 13047000 | 133384000 |
| Friday, January 1, 2016 | 11253000 | 179997000 |
| Sunday, January 1, 2017 | 13933000 | 220119000 |
| Monday, January 1, 2018 | 29514000 | 258528000 |
| Tuesday, January 1, 2019 | 37121000 | 198205000 |
| Wednesday, January 1, 2020 | 67929000 | 181022000 |
| Friday, January 1, 2021 | 118818000 | 198359000 |
| Saturday, January 1, 2022 | 159371000 | 208789000 |
| Sunday, January 1, 2023 | 213894000 | 211124000 |
Igniting the spark of knowledge
In the ever-evolving landscape of the pharmaceutical industry, understanding the financial health of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of BioCryst Pharmaceuticals, Inc. and MiMedx Group, Inc. from 2014 to 2023. Over this period, BioCryst Pharmaceuticals has seen a staggering increase in SG&A expenses, growing by nearly 2800% from 2014 to 2023. In contrast, MiMedx Group's expenses have shown a more modest increase of approximately 133% over the same period.
The data reveals a significant shift in spending strategies, with BioCryst's expenses surpassing MiMedx's by 2023. This trend may indicate BioCryst's aggressive expansion or investment in administrative capabilities. Investors and industry analysts should consider these trends when evaluating the companies' operational efficiencies and future growth potential.
Breaking Down SG&A Expenses: Zoetis Inc. vs BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
Jazz Pharmaceuticals plc vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and MiMedx Group, Inc.
SG&A Efficiency Analysis: Comparing Opthea Limited and BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Opthea Limited and MiMedx Group, Inc.
Breaking Down SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs MiMedx Group, Inc.
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and MiMedx Group, Inc.
MorphoSys AG vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing ImmunityBio, Inc. and MiMedx Group, Inc.
Supernus Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Soleno Therapeutics, Inc. vs MiMedx Group, Inc. Trends and Insights